公司资料
Trevena 股价、新闻与催化剂
- 股票代码:
- TRVN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.00 USD (0.00%)
收盘价
最后更新: 2026年8月17日
—
市值
股价为何变动
Current closing-price context is not available for TRVN.
公司概览
业务概览
Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.
所在地与行业分类
Trevena was headquartered in the United States and listed on NASDAQ, placing it in the small-cap biopharmaceutical category. It sat in the high-risk neuroscience and pain niche rather than broad healthcare.
商业模式特征
The business model was driven by late-stage development, product commercialization attempts, and the ability to secure reimbursement and physician adoption. Investors watched clinical data, product launches, and the company's capital structure closely.
生物医药行业定位
Trevena occupied a catalyst-sensitive small-cap CNS niche. It is best viewed as a legacy specialty-pharma story where execution risk and funding pressure were always central to the stock.
未来催化剂
- Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone. The market no longer treats it as a live growth name.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。